NADAC acquisition cost data for RAYALDEE ER 30 MCG CAPSULE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 70301100101 | $36.57 | 2022-08-17 | Rx |
| 70301100102 | $36.57 | 2022-08-17 | Rx |
| 70301100101 | $36.57 | 2022-08-17 | Rx |
| 70301100102 | $36.57 | 2022-08-17 | Rx |
| 70301100101 | $36.57 | 2022-08-17 | Rx |
| 70301100102 | $36.57 | 2022-08-17 | Rx |
| 70301100101 | $36.57 | 2022-08-17 | Rx |
| 70301100102 | $36.57 | 2022-08-17 | Rx |
| 70301100101 | $36.57 | 2022-08-17 | Rx |
| 70301100102 | $36.57 | 2022-08-17 | Rx |
Generic: Calcifediol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $45.9M | 34,111 | 6,659 | $36.60 |
| 2020 | $61.3M | 44,119 | 6,792 | $36.92 |
| 2021 | $39.6M | 28,393 | 4,919 | $39.56 |
| 2022 | $36.1M | 26,091 | 4,175 | $40.03 |
| 2023 | $41.5M | 29,444 | 4,889 | $41.68 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $6.5M | 4,732 | 714 |
| Texas | $6.1M | 4,350 | 775 |
| Georgia | $3.6M | 2,613 | 435 |
| New York | $3.0M | 2,020 | 382 |
| Florida | $2.5M | 1,731 | 322 |
| New Jersey | $2.1M | 1,569 | 242 |
| Ohio | $2.0M | 1,395 | 221 |
| Arizona | $1.8M | 1,214 | 204 |
| Louisiana | $1.8M | 1,358 | 232 |
| Pennsylvania | $1.7M | 1,122 | 183 |
| Alabama | $1.4M | 937 | 152 |
| Tennessee | $1.1M | 771 | 128 |
| Illinois | $838.8K | 515 | 84 |
| North Carolina | $631.1K | 477 | 70 |
| Missouri | $604.8K | 409 | 69 |
| Mississippi | $495.2K | 388 | 63 |
| Kentucky | $488.3K | 347 | 63 |
| Maryland | $456.0K | 275 | 50 |
| Oklahoma | $439.7K | 329 | 64 |
| Indiana | $407.8K | 308 | 44 |
| South Carolina | $351.5K | 248 | 48 |
| Arkansas | $336.4K | 270 | 42 |
| Nevada | $318.7K | 231 | 40 |
| Michigan | $295.5K | 223 | 53 |
| Virginia | $295.3K | 241 | 44 |
| Massachusetts | $282.9K | 209 | 31 |
| Delaware | $231.9K | 122 | 26 |
| Wisconsin | $220.1K | 155 | 33 |
| District of Columbia | $181.1K | 144 | 23 |
| West Virginia | $162.4K | 102 | 17 |
| Colorado | $159.0K | 108 | 15 |
| Kansas | $149.2K | 110 | 14 |
| Oregon | $112.6K | 90 | 12 |
| New Mexico | $89.2K | 58 | 15 |
| Connecticut | $82.8K | 42 | 11 |
| Minnesota | $77.1K | 62 | N/A |
| Washington | $76.7K | 38 | N/A |
| Utah | $50.8K | 32 | N/A |
| Nebraska | $46.7K | 43 | N/A |
| Rhode Island | $20.7K | 16 | N/A |
| Iowa | $8.7K | 13 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.